SK Capital Partners has completed the acquisition of a majority stake in SEQENS along with the merger of Wavelength Pharmaceuticals into SEQENS to create an integrated global API CDMO leader.
The merger creates a scaled leader of global industrial footprint and further extends both companies’ broad portfolio of products, services and advanced pharmaceutical technologies, while maintaining their strong culture of quality, regulatory compliance and commitment for exceptional customer service.
SEQENS is now one of the world’s leading players in pharmaceutical solutions and specialty ingredients, with annual revenues of €1.1 billion, 24 manufacturing sites, 10 R&D centers and 3,200 employees worldwide.
The combined company has a broad portfolio of products with more than 200 active pharmaceutical ingredients, 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals. Advanced technology platforms include custom polymers, lipids, flow chemistry, biocatalysis particle design, bioavailability enhancing solutions, highly potent and controlled substances.
For more information about SEQENS please visit
For more information about SK Capital please visit